scholarly journals Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients

2012 ◽  
Vol 67 (8) ◽  
pp. 2034-2042 ◽  
Author(s):  
F. Pea ◽  
P. Viale ◽  
P. Cojutti ◽  
B. Del Pin ◽  
E. Zamparini ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Term Treatment ◽  
Adult Patients ◽  
Therapeutic Drug ◽  
Long Term Treatment ◽  
Safety Outcomes

scholarly journals Successful and safe long‐term treatment of cerebral aspergillosis with high‐dose voriconazole guided by therapeutic drug monitoring

2018 ◽  
Vol 85 (1) ◽  
pp. 266-269 ◽  
Author(s):  
Pier Giorgio Cojutti ◽  
Maria Merelli ◽  
Lorenzo Allegri ◽  
Giuseppe Damante ◽  
Matteo Bassetti ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Term Treatment ◽  
Therapeutic Drug ◽  
High Dose ◽  
Long Term Treatment

scholarly journals Isavuconazole Therapeutic Drug Monitoring during Long-Term Treatment for Chronic Pulmonary Aspergillosis

2020 ◽  
Vol 65 (1) ◽  
pp. e01511-20
Author(s):  
Chris Kosmidis ◽  
Akan Otu ◽  
Caroline B. Moore ◽  
Malcolm D. Richardson ◽  
Riina Rautemaa-Richardson
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Adverse Events ◽  
Drug Monitoring ◽  
Therapeutic Drug ◽  
Pulmonary Aspergillosis ◽  
Drug Levels ◽  
Long Term Treatment ◽  
Daily Dose ◽  
Chronic Pulmonary Aspergillosis

ABSTRACTIsavuconazole is the newest triazole antifungal, and it displays a favorable pharmacokinetic and safety profile. Less is known about its long-term use in immunocompetent hosts. We performed a retrospective service evaluation of isavuconazole therapeutic drug monitoring in patients with chronic pulmonary aspergillosis. Adverse events (AEs) and dose adjustments made during routine clinical practice were recorded, and AEs were classified based on Common Terminology Criteria for Adverse Events v5.0. Forty-five patients (mean age, 64 years) had 285 isavuconazole blood drug levels measured (mean level, 4.1 mg/liter). A total of 117 measurements (41%) were performed on patients on a 100-mg daily dose instead of 200 mg, and all had blood levels of >1 mg/liter. Age (P = 0.012) and a daily dose of 200 mg versus 100 mg (P = 0.02) were independent predictors of levels of >6 mg/liter. AEs were recorded for 25 patients (56%). The mean drug level at the first measurement was 5.5 ± 2 mg/liter for patients reporting AEs, compared with 4.2 ± 1.7 mg/liter for those not reporting AEs (P = 0.032). The cutoff threshold best predictive of an AE was 4.6 mg/liter (area under the concentration-time curve, 0.710). Sixteen patients (36%) discontinued isavuconazole therapy due to AEs. Twenty-six patients (58%) continued on isavuconazole beyond 6 months. Asthma (P = 0.022) and a daily dose of 200 mg versus 100 mg (P = 0.048) were associated with AEs of grade 2 or higher. A reduced daily dose (100 mg versus 200 mg) of isavuconazole resulted in satisfactory drug levels in a substantial number of patients; it was better tolerated and enabled continuation of therapy for prolonged periods.

scholarly journals Successful Long-Term Treatment of Cerebral Nocardiosis with Unexpectedly Low Doses of Linezolid in an Immunocompromised Patient Receiving Complex Polytherapy

2012 ◽  
Vol 56 (6) ◽  
pp. 3438-3440 ◽  
Author(s):  
Federico Pea ◽  
Piergiorgio Cojutti ◽  
Alberto Pagotto ◽  
Francesco Cristini ◽  
Mario Furlanut ◽  
...  
Keyword(s):  
Mortality Rate ◽  
Therapeutic Drug Monitoring ◽  
Immunocompromised Patient ◽  
Severe Infection ◽  
Term Treatment ◽  
Therapeutic Drug ◽  
Low Doses ◽  
Long Term Treatment ◽  
Cerebral Nocardiosis

ABSTRACTCerebral nocardiosis is a severe infection that carries the highest mortality rate among all bacterial cerebral abscesses. We report on a case in an immunocompromised patient which was successfully treated with unexpectedly low doses of linezolid. Therapeutic drug monitoring was very helpful in highlighting issues of poor compliance and of drug-drug interactions.

Long-term therapeutic drug monitoring of clozapine and metabolites in psychiatric in- and outpatients

2000 ◽  
Vol 152 (1) ◽  
pp. 80-86 ◽  
Author(s):  
Michael Dettling ◽  
Christoph Sachse ◽  
Jürgen Brockmöller ◽  
Jürgen Schley ◽  
Bruno Müller-Oerlinghausen ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Therapeutic Drug

scholarly journals FP858FIRST REPORT OF THERAPEUTIC DRUG MONITORING OF AZATHIOPRINE IN LONG−TERM RENAL TRANSPLANT SURVIVORS − WHAT IS THE DESIRABLE RANGE TO TARGET?

2015 ◽  
Vol 30 (suppl_3) ◽  
pp. iii364-iii364
Author(s):  
Jennifer R Joslin ◽  
Paul Blaker ◽  
Oliver Tavabie ◽  
Benjamin White ◽  
Anthony Marinaki ◽  
...  
Keyword(s):  
Renal Transplant ◽  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Therapeutic Drug

Is There a Role for Therapeutic Drug Monitoring of Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease

2015 ◽  
Vol 33 (Suppl. 1) ◽  
pp. 70-77 ◽  
Author(s):  
Filip Baert
Keyword(s):  
Monoclonal Antibodies ◽  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Treatment Guidelines ◽  
Therapeutic Drug ◽  
Serum Concentrations ◽  
Short Term ◽  
Clear Dose Response ◽  
Inflammatory Bowel

In recent years it has become clear that therapeutic drug monitoring can be an important tool to optimize outcome and costs of anti TNF treatment including the subcutaneous and fully human monoclonal antibodies. There is a clear dose response curve between early serum concentrations of all monoclonal antibodies and response both short term and long term. The wide variations in early serum concentrations are insufficiently explained by classic pharmacokinetic factors. Low early concentrations can lead to anti-drug antibody formation and ensuing loss of response. Therapeutic drug monitoring allows to rationalize the current practice of dose optimization and the use of concomitant immunomodulator treatment. However more prospective studies are needed before strong recommendations can enter treatment guidelines.

Sign in / Sign up

Export Citation Format

Share Document